Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies

A profound difference between cancer and normal tissues is the preferential utilization of glycolysis by cancer cells. To translate this paradigm in the clinic, we completed a phase I study of 2‐deoxyglucose (2DG), and assessed 2DG uptake with fluorodeoxyglucose (FDG) positron emission tomography (PET) and the autophagy substrate p62 as a marker of 2DG resistance.

[1]  N. Savaraj,et al.  Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). , 2002, Biochemical pharmacology.

[2]  R. DiPaola,et al.  National cooperative group trials. , 2005, Urology.

[3]  Gyan Bhanot,et al.  Autophagy Suppresses Tumorigenesis through Elimination of p62 , 2009, Cell.

[4]  J. B. Wolfe,et al.  Localization of the primary metabolic block produced by 2-deoxyglucose. , 1957, The Journal of biological chemistry.

[5]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[6]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  B. Dwarakanath,et al.  Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.

[8]  E. White,et al.  A novel proteomic coculture model of prostate cancer cell growth , 2004, Proteomics.

[9]  Howard L McLeod,et al.  PI3K/Akt/mTOR pathway as a target for cancer therapy , 2005, Anti-cancer drugs.

[10]  David M Sabatini,et al.  An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.

[11]  B. Potter,et al.  2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer , 2008, British Journal of Cancer.

[12]  A. López-Rivas,et al.  Inhibition of Glucose Metabolism Sensitizes Tumor Cells to Death Receptor-triggered Apoptosis through Enhancement of Death-inducing Signaling Complex Formation and Apical Procaspase-8 Processing* , 2003, The Journal of Biological Chemistry.

[13]  J. Downward.  PI 3-kinase, Akt and cell survival. , 2004, Seminars in cell & developmental biology.

[14]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[15]  E. White,et al.  The Double-Edged Sword of Autophagy Modulation in Cancer , 2009, Clinical Cancer Research.

[16]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[17]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[18]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[19]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[20]  David J Foran,et al.  Therapeutic starvation and autophagy in prostate cancer: A new paradigm for targeting metabolism in cancer therapy , 2008, The Prostate.

[21]  J. M. Arbeit,et al.  Selective depletion of tumor ATP by 2-deoxyglucose and insulin, detected by 31P magnetic resonance spectroscopy. , 1992, Cancer research.

[22]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[23]  Awtar Krishan,et al.  Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions , 2004, Cancer Chemotherapy and Pharmacology.

[24]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[25]  R. Mccomb,et al.  METABOLISM OF ASCITES TUMOR CELLS. IV. ENZYMATIC REACTIONS INVOLVED IN ADENOSINETRIPHOSPHATE DEGRADATION INDUCED BY 2-DEOXYGLUCOSE. , 1964, Cancer research.